Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: A 30-day, randomized, double-masked, artificial tear substitute-controlled trial-Reference-Cited by-同舟云学术

Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: A 30-day, randomized, double-masked, artificial tear substitute-controlled trial

Published:2005-09 Issue:9 Volume:27 Page:1392-1402
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Avunduk Avni Murat,Tekelioglu Yavuz,Turk Adem,Akyol Nurettin

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference27 articles.

1. Epidemiology of hay fever and perennial allergic rhinitis;Weeke;Monogr Allergy,1987

2. Differential diagnosis of ocular allergic disorders;Abelson;Ann Allergy,1993

3. Ocular allergy;Allansmith;Clin Allergy,1988

4. Flow cytometry tear analysis in patients with chronic allergic conjunctivitis;Avunduk;Jpn J Ophthalmol,1997

5. The role of conjunctival epithelial cells in chronic ocular allergic disease;Hingorani;Exp Eye Res,1998

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence-based use of antihistamines for treatment of allergic conditions;Annals of Allergy, Asthma & Immunology;2023-10

2. Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis;International Journal of Ophthalmology;2023-02-18

3. Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study;Advances in Dermatology and Allergology;2023

4. Clinical trials and future perspectives of antiinflammatory agents;Recent Developments in Anti-Inflammatory Therapy;2023

5. EFFICACY OF OLOPATADINE HYDROCHLORIDE (0.1%) VERSUS KETOTIFEN FUMARATE (0.025%) OPHTHALMIC SOLUTION IN RELIEVING ITCHING IN ALLERGIC CONJUNCTIVITIS IN POPULATION OF PESHAWAR, PAKISTAN;GOMAL J MED SCI;2022